Luye Pharma Group (FRA:LUP) COGS-to-Revenue : 0.34 (As of Dec. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Luye Pharma Group COGS-to-Revenue?

Luye Pharma Group's Cost of Goods Sold for the six months ended in Dec. 2024 was €133.9 Mil. Its Revenue for the six months ended in Dec. 2024 was €391.8 Mil.

Luye Pharma Group's COGS to Revenue for the six months ended in Dec. 2024 was 0.34.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Luye Pharma Group's Gross Margin % for the six months ended in Dec. 2024 was 65.81%.

Luye Pharma Group COGS-to-Revenue Historical Data

The historical data trend for Luye Pharma Group's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Luye Pharma Group COGS-to-Revenue Chart

Luye Pharma Group Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

COGS-to-Revenue

Get a 7-Day Free Trial

0.28

0.35

0.31

0.32

0.33

Luye Pharma Group Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
COGS-to-Revenue	Get a 7-Day Free Trial															0.33	0.33	0.30	0.32	0.34

Luye Pharma Group COGS-to-Revenue Calculation

Luye Pharma Group's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	264.595	/	795.071
	=	0.33

Luye Pharma Group's COGS to Revenue for the quarter that ended in Dec. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	133.947	/	391.782
	=	0.34

Luye Pharma Group (FRA:LUP) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Luye Pharma Group's Gross Margin % for the six months ended in Dec. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	133.947 / 391.782
	=	65.81 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Luye Pharma Group COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Luye Pharma Group's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Luye Pharma Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Luye Pharma Group Ltd (FRA:LUP) » Definitions » COGS-to-Revenue

Traded in Other Exchanges

LYPHF:USA 02186:Hong Kong

Address

Hongqiao Road 1438, 22/F, Gubei International Fortune Center II, Changning District, Shanghai, CHN, 264003

Website

https://www.luye.cn

Luye Pharma Group Ltd is a China-based drug manufacturer that focuses on development, production, marketing and sale of pharmaceutical products. The company develops drugs related to diagnosing and treating cancer, the cardiovascular system, the alimentary tract, and the central nervous system. The company's highest revenue share comes from oncology drugs, followed by central nervous system drugs. The company develops drugs for world-wide use in Asia, Europe, and the United States. The Group organizes its business segments by type of products. Oncology drugs, Cardiovascular system drugs, Alimentary tract and metabolism drugs and Central nervous system drugs. It derives maximum revenue from the sale of Oncology drugs.

Luye Pharma Group Headlines

No Headlines